Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Hemab Therapeutics Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Hemab Therapeutics Holdings, Inc.’s stock price such as:

• Hemab Therapeutics Holdings, Inc.’s current stock price and volume
• Why Hemab Therapeutics Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for COAG from analysts
• COAG’s stock price momentum as measured by its relative strength

About Hemab Therapeutics Holdings, Inc. (COAG)

Before we jump into Hemab Therapeutics Holdings, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Want to learn more about Hemab Therapeutics Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Hemab Therapeutics Holdings, Inc..

Hemab Therapeutics Holdings, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Hemab Therapeutics Holdings, Inc.’s stock price was $47.550.

Hemab Therapeutics Holdings, Inc. is up 0.17% from its previous closing price of $47.470.

During the last market session, Hemab Therapeutics Holdings, Inc.’s stock traded between $45.440 and $48.620. Currently, there are approximately 0.95 million shares outstanding for Hemab Therapeutics Holdings, Inc..

Hemab Therapeutics Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Hemab Therapeutics Holdings, Inc. Stock Price History

Hemab Therapeutics Holdings, Inc.’s (COAG) price is currently up 29.46% so far this month.

During the month of July, Hemab Therapeutics Holdings, Inc.’s stock price has reached a high of $52.150 and a low of $29.540.

Over the last year, Hemab Therapeutics Holdings, Inc. has hit prices as high as $52.145 and as low as $23.000.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Hemab Therapeutics Holdings, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Hemab Therapeutics Holdings, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Hemab Therapeutics Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Hemab Therapeutics Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Hemab Therapeutics Holdings, Inc. (COAG) by visiting AAII Stock Evaluator.

Relative Price Strength of Hemab Therapeutics Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Hemab Therapeutics Holdings, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Hemab Therapeutics Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Hemab Therapeutics Holdings, Inc. Stock Price: Bottom Line

As of July 31, 2026, Hemab Therapeutics Holdings, Inc.’s stock price is $47.550, which is up 0.17% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Hemab Therapeutics Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.